BioSpace

BioSpace
  • 0,0 (0)
  • Бионауки
  • Еженедельно

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. -1 дн.

    Rewriting the rules of CMV prevention

    In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ian McGowan, CMO, Synklino James Hunter, Associate Professor of Transplantation, Oxford University Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. Custom Fields

    Rewriting the rules of CMV prevention

  2. -2 дн.

    Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

    Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

    Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

  3. 13 авг.

    The Italian inflection point: Clinical strength, culture and capital

    In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Diana Saraceni, Founder and Managing Partner, Panakès Partners Fabrizio Calisti, Medical Director, Angelini Ventures Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The Italian inflection point: Clinical strength, culture and capital

  4. 12 авг.

    Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

    After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

    Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

  5. 11 авг.

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

  6. 6 авг.

    The next treatment-resistant depression paradigm

    In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hans Eriksson, Chief Medical Officer, FundaMental Pharma Steve Levine, Chief Patient Officer, Compass Pathways Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The next treatment-resistant depression paradigm

  7. 30 июл.

    Life after the lead asset: Advancing an early-stage pipeline

    In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with Arvinas. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guest Randy Teel, President and CEO, Arvinas

    Life after the lead asset: Advancing an early-stage pipeline

  8. 29 июл.

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

    The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
См. все (258)

Об этом подкасте

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Информация

  • Автор
    BioSpace
  • Годы выхода
    2023 - 2026
  • Выпуски
    258
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2026 BioSpace
  • Сайт подкаста
    BioSpace

Вам может также понравиться